EP4 as a Therapeutic Target for Aggressive Human Breast Cancer

@article{Majumder2018EP4AA,
  title={EP4 as a Therapeutic Target for Aggressive Human Breast Cancer},
  author={M. Majumder and P. Nandi and A. Omar and K. Ugwuagbo and P. Lala},
  journal={International Journal of Molecular Sciences},
  year={2018},
  volume={19}
}
G-protein-coupled receptors (GPCRs, also called seven-transmembrane or heptahelical receptors) are a superfamily of cell surface receptor proteins that bind to many extracellular ligands and transmit signals to an intracellular guanine nucleotide-binding protein (G-protein). When a ligand binds, the receptor activates the attached G-protein by causing the exchange of Guanosine-5′-triphosphate (GTP) for guanosine diphosphate (GDP). They play a major role in many physiological functions, as well… Expand
Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy
TLDR
There is growing evidence that EP4 antagonism, particularly in combination with either chemotherapy, endocrine therapy, or immune-based therapies, should be investigated further as a promising novel approach to cancer therapy. Expand
Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis
TLDR
COX-2 is a major promoter of both events, primarily resulting from the activation of prostaglandin E receptor EP4 on tumor cells, tumor-infiltrating immune cells, and endothelial cells; and induction of oncogenic microRNAs. Expand
EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
TLDR
Antagonism of the EP3 receptor results in a reduced proliferation and migration of SK-BR-3 breast cancer cells, potentially mediated via a Gi-protein-cAMP pathway and suggests that EP3 plays a role in tumorigenesis. Expand
Eicosanoids in Cancer: New Roles in Immunoregulation
TLDR
The existence of small molecular inhibitors and activators of eicosanoid pathways such as specific receptor blockers make them attractive candidates for therapeutic trials, especially in combination with novel immunotherapies such as immune checkpoint inhibitors. Expand
Prostaglandin E2 receptor EP4 regulates cell migration through Orai1
TLDR
The data suggested that EP4 activated PI3K and then induced Ca2+ influx from the extracellular space through Orai 1, resulting in ERK phosphorylation and promoting cell migration, which is regulated by EP4/PI3K/Orai1 signaling in oral cancer. Expand
EP4 as a Therapeutic Target to Impede Breast Cancer-associated Angiogenesis and Lymphangiogenesis
TLDR
It is shown that COX-2 is a major promoter of both events, primarily resulting from the activation of Prostaglandin E receptor EP4 on tumor cells, tumor-infiltrating immune cells, and endothelial cells; and induction of oncogenic microRNAs. Expand
COX-2-PGE2-EPs in gynecological cancers
TLDR
An overview of the current knowledge of COX-2-PGE2-EPs signaling in endometrial cancer, ovarian cancer and cervical cancer is provided and EPs represent promising anti-inflammation biomarkers for gynecological cancer and may be novel treatment targets in the near future. Expand
Characterization of miR-574-5p decoy to CUGBP1 in human lung cancer cells using a mass spectrometry proteomics approach
TLDR
A proteomics approach was conducted in order to gather global insights into the proteome changes related to miR-574-5p and CUGBP1, especially in a compartment specific manner and it is assumable that this novel decoy mechanism is specifically regulating mPGES-1 in A549 lung cancer cells. Expand
Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155
TLDR
The data suggest an alternative way for suppressing PGE2 production via the inhibition of miR-155, which significantly correlates with breast cancer patients’ survival. Expand
miR-655: a promising regulator with therapeutic potential.
TLDR
The results indicate that miR-655-related genes are involved in cancer cell proliferation, migration, invasion, and apoptosis, and various biological processes such as angiogenesis, EMT, and oxidative stress. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 109 REFERENCES
G protein-coupled receptors as promising cancer targets.
TLDR
Tumor related GPCRs, such as G protein-coupled receptor 30, the lysophosphatidic acid receptor, angiotensin receptors 1 and 2, the sphingosine 1-phosphate receptors and gastrin releasing peptide receptor are focused on. Expand
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
TLDR
While preclinical and epidemiological data support the use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors (COXibs) for the prevention and treatment of malignancy, toxicities due to COXIBs as well as less than promising results from clinical trials have laboratories seeking alternative targets. Expand
G protein-coupled receptors: novel targets for drug discovery in cancer
TLDR
This work reviews recent findings that present unexpected opportunities to interfere with major tumorigenic signals by manipulating GPCR-mediated pathways and discusses current data regarding novel G PCR targets that may provide promising opportunities for drug discovery in cancer prevention and treatment. Expand
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
TLDR
These studies support the continued investigation of EP4 as a potential therapeutic target and provide new insight regarding the role ofEP4 in supporting a breast cancer stem cell/tumor-initiating phenotype. Expand
E-type prostanoid receptor 4 (EP4) in disease and therapy
TLDR
The present review attempts to summarize the EP4 receptor-triggered signaling modules and the possible therapeutic applications of EP4-selective agonists and antagonists. Expand
Role of β-arrestin 1 in the metastatic progression of colorectal cancer
TLDR
The results show that the prostaglandin E/β-arrestin 1/c-Src signaling complex is a crucial step in PGE2-mediated transactivation of the EGFR and may play a pivotal role in tumor metastasis. Expand
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
TLDR
The expression of EP receptors and their roles in migratory function of breast cancer cells of murine and human (MDA-MB-231 and MCF-7) origin are defined and exogenous PGE2 and EP4 agonist PGE1 alcohol increased migration of C3L5 cells. Expand
EP4 receptor promotes invadopodia and invasion in human breast cancer.
TLDR
The results show that stimulation with the selective EP4 agonist CAY10598 or PGE2 promotes invadopodia-mediated degradation of the ECM, as well as the invasion of breast cancer cells in in vitro models, and highlights the importance of further investigation on the role of EP4-EGFR crosstalk in invadobodia formation. Expand
Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?
TLDR
This review focuses on PGE2, and in particular on the role of the individual EP receptors and their signalling pathways in neoplastic disease, and the potential for exploiting the EP receptors as therapeutic targets for the treatment of cancer and metastatic disease. Expand
Prostanoid receptors: subtypes and signaling.
TLDR
Alternative splice variants described that alter the coding sequence in the C-terminal intracellular tail region modulate signal transduction, phosphorylation, and desensitization of these receptors, as well as altering agonist-independent constitutive activity. Expand
...
1
2
3
4
5
...